OR WAIT 15 SECS
Rita C. Peters is editorial director of BioPharm International, Pharmaceutical Technology, and Pharmaceutical Technology Europe.
Technology and capacity investments create opportunities in the cell and gene therapy arena for CDMOs and biopharma alike.
Emerging therapies are testing the capabilities of biologic drug manufacturing companies, as well as contract development and manufacturing organizations (CDMOs) and contract manufacturing organizations (CMOs). Manufacturers are employing process optimization and scalable advanced technologies to produce more product in less floor space. In addition, CDMOs have stepped up investments in cell and gene therapy development and manufacturing While this consolidation means there are fewer competitors in the market, industry experts see benefits including standardization of methods, simplified vendor management, and use of advanced technologies.
eBook: Outsourcing Resources, February 2020
When referring to this article, please cite it as R.Peters, “More Capacity and Technology Translate to More Options," BioPharm International Outsourcing ResourceseBook (February 2020).